Foscan

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

temoporfin

Available from:

Biolitec Pharma Ltd

ATC code:

L01XD05

INN (International Name):

temoporfin

Therapeutic group:

Antineoplastična sredstva

Therapeutic area:

Head and Neck Neoplasms; Carcinoma, Squamous Cell

Therapeutic indications:

Foscan je indiciran za paliativno zdravljenje bolnikov z napredovalim karcinomom skvamoznih celic glave in vratu, ki niso prejeli terapije in niso primerni za radioterapijo, kirurgijo ali sistemsko kemoterapijo.

Product summary:

Revision: 18

Authorization status:

Pooblaščeni

Authorization date:

2001-10-24

Patient Information leaflet

                                16
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 ºC.
Shranjujte v originalni ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
biolitec Pharma Ltd.
Otto-Schott-Str. 15
07745 Jena
Nemčija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/01/197/003 (1 ml)
EU/1/01/197/004 (3 ml)
EU/1/01/197/005 (6 ml)
13.
ŠTEVILKA SERIJE
serija
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
OZNAKA VIALE 1 MG/ML
1.
IME ZDRAVILA IN POT(I) UPORABE
Foscan 1 mg/ml raztopina za injiciranje
temoporfin
intravenska uporaba
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Serija
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
1 mg/1 ml
3 mg/3 ml
6 mg/6 ml
6.
DRUGI PODATKI
18
B. NAVODILO ZA UPORABO
19
NAVODILO ZA UPORABO
FOSCAN 1 MG/ML RAZTOPINA ZA INJICIRANJE
temoporfin
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate dodatna vprašanja, se posvetujte z zdravnikom ali
medicinsko sestro.
-
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom
ali medicinsko sestro.
Posvetujte se tudi, če opazite katere koli neželene učinke, ki niso
navedeni v tem navodilu.
Glejte poglavje 4.
KAJ VSEBUJE NAVODILO
1.
Kaj je zdravilo Foscan in za kaj ga uporabljamo
2.
Kaj morate vedeti, preden boste uporabili zdravilo Foscan
3.
Kako uporabljati zdravilo Foscan
4.
Možni neželeni učinki
5.
Shranjevanje zdravila Foscan
6.
Vsebina pakiranja in dodatne informacije
1.
KAJ JE ZDRAVILO FOSCAN IN ZA KAJ GA UPORABLJAMO
Zdravilna učinkovina v zdravilu 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Foscan 1 mg/ml raztopina za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
En ml vsebuje 1 mg temoporfina.
_Pomožne snovi z znanim učinkom_:
En ml vsebuje 376 mg brezvodnega etanola in 560 mg propilenglikola.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
raztopina za injiciranje
temno vijolična raztopina
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Foscan je indicirano za paliativno zdravljenje bolnikov z
napredovalim ploščatoceličnim
rakom glave in vratu, pri katerih prejšnja zdravljenja niso bila
uspešna in niso primerni za
radioterapijo, kirurški poseg ali sistemsko kemoterapijo.
4.2
ODMERJANJE IN NAČIN UPORABE
Fotodinamično zdravljenje z zdravilom Foscan se lahko izvaja le v
specialističnih onkoloških centrih,
kjer multidisciplinarna ekipa določi zdravljenje bolnika, in pod
nadzorom zdravnikov, ki že imajo
izkušnje s fotodinamičnim zdravljenjem.
Odmerjanje
Odmerek je 0,15 mg/kg telesne mase.
_Pediatrična populacija _
Zdravilo Foscan ni namenjeno za uporabo pri pediatrični populaciji.
Način uporabe
Zdravilo Foscan apliciramo skozi stalno vensko kanilo v večjo
proksimalno žilo uda, po možnosti v
antekubitalni fosi z enkratnim počasnim intravenskim injiciranjem, ki
ne sme trajati manj kot 6 minut.
Pred injiciranjem je treba preizkusiti prehodnost stalne kanile in
paziti, da ne pride do ekstravazacije
(glejte poglavje 4.4).
Zaradi temno vijolične barve raztopine in rumenkasto rjave barve vial
ni mogoče videti, ali raztopina
vsebuje delce. Zato je potrebno kot varnostni ukrep uporabiti
zaporedni filter, ki je priložen v
pakiranju. Zdravila Foscan ne smete redčiti ali izpirati z natrijevim
kloridom ali katero koli drugo
vodno raztopino.
Ustrezen odmerek zdravila Foscan aplicirajte s počasnim intravenskim
injiciranjem najmanj 6 minut.
96 ur po aplikaciji zdravila Foscan mora biti zdravljeno mesto
obsevano s predpisano lasersko
svetlobo valovne dolžine 652 nm. Svetloba mora 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 18-04-2016
Summary of Product characteristics Summary of Product characteristics Bulgarian 18-04-2016
Public Assessment Report Public Assessment Report Bulgarian 18-04-2016
Patient Information leaflet Patient Information leaflet Spanish 18-04-2016
Public Assessment Report Public Assessment Report Spanish 18-04-2016
Patient Information leaflet Patient Information leaflet Czech 18-04-2016
Public Assessment Report Public Assessment Report Czech 18-04-2016
Patient Information leaflet Patient Information leaflet Danish 18-04-2016
Public Assessment Report Public Assessment Report Danish 18-04-2016
Patient Information leaflet Patient Information leaflet German 18-04-2016
Public Assessment Report Public Assessment Report German 18-04-2016
Patient Information leaflet Patient Information leaflet Estonian 18-04-2016
Public Assessment Report Public Assessment Report Estonian 18-04-2016
Patient Information leaflet Patient Information leaflet Greek 18-04-2016
Public Assessment Report Public Assessment Report Greek 18-04-2016
Patient Information leaflet Patient Information leaflet English 18-04-2016
Public Assessment Report Public Assessment Report English 18-04-2016
Patient Information leaflet Patient Information leaflet French 18-04-2016
Public Assessment Report Public Assessment Report French 18-04-2016
Patient Information leaflet Patient Information leaflet Italian 18-04-2016
Public Assessment Report Public Assessment Report Italian 18-04-2016
Patient Information leaflet Patient Information leaflet Latvian 18-04-2016
Public Assessment Report Public Assessment Report Latvian 18-04-2016
Patient Information leaflet Patient Information leaflet Lithuanian 18-04-2016
Summary of Product characteristics Summary of Product characteristics Lithuanian 18-04-2016
Public Assessment Report Public Assessment Report Lithuanian 18-04-2016
Patient Information leaflet Patient Information leaflet Hungarian 18-04-2016
Summary of Product characteristics Summary of Product characteristics Hungarian 18-04-2016
Public Assessment Report Public Assessment Report Hungarian 18-04-2016
Patient Information leaflet Patient Information leaflet Maltese 18-04-2016
Public Assessment Report Public Assessment Report Maltese 18-04-2016
Patient Information leaflet Patient Information leaflet Dutch 18-04-2016
Public Assessment Report Public Assessment Report Dutch 18-04-2016
Patient Information leaflet Patient Information leaflet Polish 18-04-2016
Public Assessment Report Public Assessment Report Polish 18-04-2016
Patient Information leaflet Patient Information leaflet Portuguese 18-04-2016
Summary of Product characteristics Summary of Product characteristics Portuguese 18-04-2016
Public Assessment Report Public Assessment Report Portuguese 18-04-2016
Patient Information leaflet Patient Information leaflet Romanian 18-04-2016
Public Assessment Report Public Assessment Report Romanian 18-04-2016
Patient Information leaflet Patient Information leaflet Slovak 18-04-2016
Public Assessment Report Public Assessment Report Slovak 18-04-2016
Patient Information leaflet Patient Information leaflet Finnish 18-04-2016
Public Assessment Report Public Assessment Report Finnish 18-04-2016
Patient Information leaflet Patient Information leaflet Swedish 18-04-2016
Public Assessment Report Public Assessment Report Swedish 18-04-2016
Patient Information leaflet Patient Information leaflet Norwegian 18-04-2016
Summary of Product characteristics Summary of Product characteristics Norwegian 18-04-2016
Patient Information leaflet Patient Information leaflet Icelandic 18-04-2016
Summary of Product characteristics Summary of Product characteristics Icelandic 18-04-2016
Patient Information leaflet Patient Information leaflet Croatian 18-04-2016
Public Assessment Report Public Assessment Report Croatian 18-04-2016

Search alerts related to this product

View documents history